CUV
Asset Logo

Clinuvel Pharmaceuticals Limited

🇦🇺 ASX

🧬 BIOTECHNOLOGY

Compare
Add to watchlist
👑 Overview

📈 Performance

💰 Dividends

💵 Cost

🍃 Esg

🤓 Advanced

👨‍👩‍👧‍👦 Community

📈

-11.25%
Annual Growth

5 years average annual growth

💰

0.34%
Annual dividend yield

Based on the most recent dividend

💵

$ 500
Minimum Order

Due to regulatory requirements

🌏

16
Pearlers Invested

Since January 2020

👑 Overview

Key information
🔎 Fund Overview

Clinuvel Pharmaceuticals Ltd. operates as a biopharmaceutical company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2001-02-13. The firm is focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialized populations. Its lead therapy, SCENESSE (afamelanotide 16mg), is approved for commercial distribution in Europe, the USA, Israel, and Australia as the first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). The Company’s pharmaceuticals product development includes PRENUMBRA and NEURACTHEL. Its PhotoCosmetics product development includes CYACELLE and DNA Repair Assist and Melanogenesis. PRENUMBRA is a formulation of afamelanotide designed to provide a flexible dose in identified patient groups. NEURACTHEL is a novel formulation of the melanocortin adrenocorticotropic hormone (ACTH).

📈 Performance

Price History

+214.22%

1M

1Y

10Y

Graph

Table

Unsure how much or often to invest?
🗓️ Investing frequency calculator

Determine the investment frequency needed to reach your goals

Try it out →
💵 Investing amount calculator

Determine the recurring investment needed to reach your goals

Try it out →
⏱️ Investing duration calculator

Determine how long you will need to invest to reach your goals

Try it out →

💰 Dividends

Payouts

💰 Annual Dividend Yield*

0.34%

💰 Annual Dividend Earnings Per $1,000 invested**

$3.37

💰 Most Recent Dividend Franked Percentage Estimate

100.00%

💰 Average Dividend Franked Percentage Estimate

100.00 %

💰 Dividend reinvestment

Learn more

* Based on the most recent dividend

** Calculated by multiplying the most recent dividend yield by $1,000

Estimate your dividend

If you held

$

of CUV, your last dividend payment(s) would have been:

$ 47.02

on Fri Sep 20 2024

$ 39.35

on Wed Sep 20 2023

*Disclaimer: The information provided in this calculator is only a model to show you how long you need to invest for to achieve your goal, based on several factors, including past performance which is not an indicator of future performance. It is not a prediction and relies on assumptions, such as interest rates, that may vary and change the actual outcome. The results shown are only estimates and are not intended to be relied on when making a financial decision. Consider whether to get advice from a licensed financial adviser before making any financial decision.

Dividend History

1Y

5Y

10Y

Graph

Table

Year
Yearly Dividend Earnings Per Share
Franking Estimate

2024

$0.00

0.00%

2023

$0.05

Infinity%

2022

$0.04

Infinity%

2021

$0.03

Infinity%

2020

$0.03

NaN%

2019

$0.03

NaN%

2018

$0.02

0.00%

2017

$0.00

0.00%

2016

$0.00

0.00%

2015

$0.00

0.00%

💵 Costs

💵

6.50 AUD*
Purchase Fee

*$5.50 with Pearler Prepay

💼

N/A
Management Fee

Included in unit price, not charged by Pearler

💸

Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator

🍃 Environmental, Social and Governance scores ℹ️

🌳

Environmental Score
3

A measure of an organisations or investment's impact on the natural environment, including factors such as carbon emissions, resource usage, and pollution

🕊️

Social Score
64

An assessment of an organisations management practices, board structure, transparency, and accountability, reflecting its commitment to ethical behavior and responsible decision-making.

⚖️

Governance Score
50

An evaluation of an organisations impact on society, focusing on factors such as employee welfare, diversity and inclusion, community engagement, and product safety and quality.

🤓 Advanced information

Technical Info

💰 Price*

$13.04

*Price may be up to 24 hours old

👩‍👩‍👦 Community Insights

How our community is investing

🌏 Pearlers invested in CUV

16

📊 Total Capital Earnings

$20K

🔃 Average investment frequency

11 weeks

💵 Average investment amount

$6,853

Last time a customer invested in CUV

4 days
CUV investor breakdown
💵 Income of investors

More than 200k

150k - 200k

100k - 150k

10%

50k - 100k

40%

Less than 50k

40%
👶 Age of investors

18 - 25

13%

26 - 34

19%

35 - 90

69%
🙋 Legal gender of investors

Female

Male

88%

Pearlers who invest in CUV also invest in...

Vanguard Australian Shares Index ETF

VAS

VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.

🙌 Performance (5Yr p.a)

4.43%

📊 Share price

$104.33 AUD

🧱 MATERIALS

⛳️ DIVERSIFIED

💸 FINANCIALS

Find Out More

Pilbara Minerals Ltd. engages in the exploration and evaluation of mineral properties. The company is headquartered in Perth, Western Australia and currently employs 768 full-time employees. The company went IPO on 2007-09-19. The firm is primarily engaged in the exploration, development, and mining of minerals in Australia. Its 100% owned Pilgangoora hard-rock lithium operation is located approximately 120 kilometers (kms) from Port Hedland in Western Australia’s resource-rich Pilbara region. The operation consists of two processing plants: the Pilgan Plant, located on the northern side of the Pilgangoora area and produces spodumene and tantalite concentrates, and the Ngungaju Plant is located to the south produces spodumene concentrate. The company owns 70% of the Mt Francisco project, which is located 50 km south-west of the Pilgangoora Project and hosts the large occurrence of outcropping pegmatites located nearby to Port Hedland. The company is also pursuing a proposed downstream joint venture (JV) for the development of an approximately 43,000 tons per annum (tpa) lithium carbonate equivalent (LCE) lithium chemical conversion facility in South Korea.

🙌 Performance (5Yr p.a)

160.75%

📊 Share price

$2.61 AUD

⛏️ MINING

Sonic Healthcare Ltd. engages in the provision of medical diagnostics services. The company is headquartered in Sydney, New South Wales and currently employs 41,000 full-time employees. The firm is engaged in laboratory medicine / pathology, radiology, and primary care medical services, across operations in Australia, Europe, and North America. The firm operates through three segments: Laboratory, Radiology and Other. The Laboratory segment provides pathology/clinical laboratory services in Australia, New Zealand, the United Kingdom, the United States of America, Germany, Switzerland, and Belgium. The Radiology segment provides diagnostic imaging services in Australia. The Radiology technologies include Magnetic resonance imaging (MRI), Computed tomography (CT), Ultrasound, X-ray, Mammography, and others. The Other segment includes medical center operations (IPN), occupational health services (Sonic HealthPlus), and other minor operations. The firm's provides services to clinicians, hospitals, community health services, and their patients. The firm has more than 120 radiology centers.

🙌 Performance (5Yr p.a)

-1.21%

📊 Share price

$27.97 AUD

🌳 ENVIRONMENTAL

🕊️ SOCIALLY AWARE

🩺 HEALTH CARE

IVV.AX was created on 2007-10-10 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.

🙌 Performance (5Yr p.a)

19.73%

📊 Share price

$61.01 AUD

📈 HIGH PRICE GROWTH

🇺🇸 UNITED STATES

ResMed, Inc. engages in providing digital health and cloud-connected medical devices. The company is headquartered in San Diego, California and currently employs 10,140 full-time employees. The Company, through its subsidiaries, is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease, neuromuscular disease and other chronic diseases. The Company’s segments include Sleep and Respiratory Care and Software as a Service. SDB includes obstructive sleep apnea and other respiratory disorders that occur during sleep. Its cloud-based digital software health applications, along with its devices, are designed to provide connected care to improve patient outcomes. Its portfolio of products includes devices, diagnostic products, mask systems, headgear and other accessories, dental devices, and cloud-based software and informatics solutions. Its comprehensive out-of-hospital software platforms support the professionals and caregivers.

🙌 Performance (5Yr p.a)

14.57%

📊 Share price

$37.28 AUD

🩺 HEALTH CARE

📈 HIGH PRICE GROWTH

🌳 ENVIRONMENTAL

🕊️ SOCIALLY AWARE

Want more shares? Try these...

CurveBeam AI Ltd. engages in the research, design, and manufacture of cone beam computed tomography imaging systems. The company is headquartered in Hatfield, Pennsylvania. The company went IPO on 2023-08-23. The firm is engaged in providing point-of-care diagnostic cone beam CT imaging solutions with artificial intelligence (AI) and deep learning AI (DLAI). Its product categories include orthopedics and bone health. Its orthopedics products include HiRise, LineUP, pedCAT Premium, pedCAT, InReach, and CubeVue Software. Its bone health products include InReach HR-pQCT, and OSSView. HiRise is a bilateral, weight bearing CT imaging of the entire lower extremities including hips/pelvis, distal upper extremities. LineUP is a bilateral, weight bearing CT imaging of the distal lower extremities and distal upper extremities. InReach HR-pQCT is a high resolution peripheral quantitative CT (HR-pQCT) imaging system designed for the point-of-care. OssView Bone Fragility software analyzes HR-pQCT images to measure the bone microarchitecture.

📊 Share price

$0.10 AUD

🩺 HEALTH CARE

CVC Ltd. engages in the provision of investment, development and venture capital, property finance and development, investment in listed entities, and funds management. The company is headquartered in Sydney, New South Wales. The firm's principal activities include property finance and development, the provision of investment and development capital and investment in other non-property opportunities. Its segments include property investment and non-property investment. The property investment segment includes investments in property related ordinary equity, preference equity, joint ventures, options to acquire an interest in direct property subject to planning outcomes and property backed lending. The non-property investment segment comprises listed investments, unlisted investments and secured lending opportunities that are non-property related. This segment also includes receivables, litigation claims and other investments. Its subsidiaries include Biggee Pty Limited, CVC Caboolture Unit Trust and Biomedical Systems Pty Limited.

🙌 Performance (5Yr p.a)

-1.10%

📊 Share price

$2.06 AUD

💸 FINANCIALS

CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index.

🙌 Performance (5Yr p.a)

-2.06%

📊 Share price

$49.30 AUD

🇺🇸 UNITED STATES

🩺 HEALTH CARE

Copper Search Ltd. is a mineral exploration and development company focused on the Gawler Craton Region of South Australia. The firm is engaged in targeting the copper-gold deposits within the Gawler Craton of South Australia. Its projects include the Peake Project, Billa Kalina Project, and North Titan Project. Its Peake project is in the NE Gawler Craton, prospective for copper (IOCG) deposits. The company has 100% ownership of the 5,560 square kilometers (km2) of the Peake Project. The project is prospective for iron-ore-copper-gold (IOCG) and iron-sulphide-copper-gold (ISCG) deposits. The firm has identified six potential IOCG drill targets from over 40 geophysical anomalies. Its tenements are held through its 100%-owned subsidiary, Copper Search Australia Pty Ltd. Its tenements include Curdimurka, Anna Creek, Allandale, Mt Arthur, Stuarts Creek, Callana, Ruby Hill, Spring Hill, Mt Denison, Blyth Creek, Dismal Plain, and Wantaman. Its drilling aims to identify IOCG target deposits with similar scale potential to Prominent Hill and Carrapateena.

📊 Share price

$0.04 AUD

⛏️ MINING

Compare
Add to watchlist